Karyopharm therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Newton, mass. , april 1, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company approved the grant of stock options to purchase an aggregate of 58,600 shares of karyopharm's common stock and an aggregate of 36,900 restricted stock units (rsus) to six newly-hired employees.
KPTI Ratings Summary
KPTI Quant Ranking